What question did this study set out to answer?

To review the pharmacokinetic and pharmacodynamic profiles of the DPP-4 inhibitor linagliptin in healthy volunteers and individuals with type 2 diabetes.

October 25, 2011Expert Opinion on Drug Metabolism & Toxicology

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

View Full Paper

Ask AI

Bookmark

Why the study?

What are the pharmacokinetic and pharmacodynamic properties of linagliptin in healthy volunteers and patients with type 2 diabetes?

Key Points

To review the pharmacokinetic and pharmacodynamic profiles of the DPP-4 inhibitor linagliptin in healthy volunteers and individuals with type 2 diabetes.
Conducted an extensive literature review assessing linagliptin pharmacokinetics and pharmacodynamics after single-dose ranges and chronic steady-state administration.
Evaluated linagliptin monotherapy and combination regimens across healthy participants and patients with type 2 diabetes, with emphasis on renal impairment and drug-drug interactions.
Linagliptin features a predominantly nonrenal route of elimination, allowing administration to patients with renal impairment without dose adjustment or kidney function monitoring.
The compound demonstrates a low potential for drug-drug interactions, with no clinically relevant interactions identified across evaluated studies.

Structured PICO

What are the pharmacokinetic and pharmacodynamic properties of linagliptin in healthy volunteers and patients with type 2 diabetes?

Population

Healthy volunteers and patients with type 2 diabetes (T2DM), including those with renal impairment

Intervention

Linagliptin

Outcome

Pharmacokinetic (PK) and pharmacodynamic (PD) characteristicssurrogate

Linagliptin offers a unique pharmacokinetic profile among DPP-4 inhibitors, notably its nonrenal elimination which simplifies dosing in patients with renal impairment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May simplify dosing in T2D with renal impairment; leaves open need for prospective outcome trials.

Cite This Study

André Scheen (2011) studied this question.

synapsesocial.com/papers/6a7cebfe6e07fdc915aeb449 https://doi.org/10.1517/17425255.2011.628986

View Full Paper

Ask AI

Bookmark

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider